ArticleFrontiers in oncology2025
Accelerating cancer genomics research in Sub-Saharan Africa.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- dbGVOSCC: a comprehensive database of genetic variation for systems genetics research on oral squamous cell carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is an increasing public health concern for Sub-Saharan African (SSA) countries, a region that is, unfortunately, already marked by the persistent presence of infectious diseases. Noticeably, in SSA, the universal approach to cancer treatment still prevails, whereas elsewhere, cancer treatment has shifted towards precision medicine. Definitely, the region faces many challenges that impede cancer genomics research despite its tremendous potential solution. Indeed, Genomics research could provide critical insights into the genetic determinants of cancers prevalent in SSA, enabling more precise and effective diagnosis, treatment, and prevention strategies tailored to local specificities. Therefore, shifting to precision medicine in this region is critical to tackle increase in cancer cases among SSA populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.